Cintora Mairal Carmen, Martín-Gutiérrez Guillermo, Rodríguez-Villodres Ángel, Cisneros José Miguel, Lepe José Antonio, Ortiz de la Rosa José Manuel
Clinical Unit of Infectious Diseases, Microbiology and Parasitology, University Hospital Virgen del Rocío, 41013 Seville, Spain.
Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío, Higher Council for Scientific Research (CSIC), University of Seville, 41013 Seville, Spain.
Antibiotics (Basel). 2025 May 9;14(5):480. doi: 10.3390/antibiotics14050480.
: Meropenem is widely used to treat Pseudomonas aeruginosa infections; however, the pathogen's increasing resistance compromises its efficacy. In this study, we aimed to develop a selective culture medium for detecting the presence of meropenem-resistant in respiratory specimens within 24 h. : The medium's performance was challenged using a collection of 130 clinical strains (of which 85 were meropenem-susceptible, 14 were meropenem-intermediate, and 21 were meropenem-resistant). Subsequently, clinical validation was carried out using 130 respiratory samples. : The selective medium demonstrated excellent sensitivity (average 98.7%) and specificity (average 90%) across bacterial concentrations ranging from 1 × 10 to 1 × 10 CFU/mL, and a high negative predictive value (average 99.2%) compared to the broth microdilution (BMD) method. Clinical validation with bronchoalveolar lavage (BAL) and tracheobronchial aspirate (TBA) clinical specimens (N = 130) revealed a strong performance, with 92,3% categorical agreement. : This method accelerates susceptibility testing, is user-friendly, and delivers reliable results, contributing to the optimization of empirical treatment for respiratory tract infections.
美罗培南广泛用于治疗铜绿假单胞菌感染;然而,该病原体日益增加的耐药性损害了其疗效。在本研究中,我们旨在开发一种选择性培养基,用于在24小时内检测呼吸道标本中耐美罗培南菌的存在。:使用130株临床菌株(其中85株对美罗培南敏感,14株对美罗培南中介,21株对美罗培南耐药)对该培养基的性能进行了验证。随后,使用130份呼吸道样本进行了临床验证。:该选择性培养基在细菌浓度范围为1×10至1×10 CFU/mL时表现出优异的敏感性(平均98.7%)和特异性(平均90%),与肉汤微量稀释(BMD)法相比具有较高的阴性预测值(平均99.2%)。对支气管肺泡灌洗(BAL)和气管支气管吸出物(TBA)临床标本(N = 130)进行的临床验证显示性能良好,分类一致性为92.3%。:该方法加快了药敏试验速度,使用方便,结果可靠,有助于优化呼吸道感染的经验性治疗。